ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 100.6 | 96.3 | 93.8 |
| Other income | 0.0 | 1.0 | 0.4 |
| Total income | 100.6 | 97.3 | 94.2 |
| Profit before exceptional items & tax | 6.8 | 5.7 | 5.5 |
| Profit before tax | 6.8 | 5.7 | 5.5 |
| Net profit | 5.4 | 4.5 | 4.3 |
| Operating margin | 6.8% | 5.9% | 5.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +25.60% |
|---|---|
| Net profit, quarter on quarter | +20.00% |
| Revenue, year on year | +7.20% |
| Operating profit, year on year | +33.30% |
| Operating profit, quarter on quarter | +44.70% |
BSE results filing, NSE: SHIVALIK. Figures extracted from the filing.
Shivalik Rasayan Ltd: key numbers
- Share price
- ₹305.15
- Market cap
- ₹489.2 Cr
- Revenue (annual)
- ₹368.0 Cr
- Net profit (annual)
- ₹12.40 Cr
- P/E (TTM)
- 34.2×Sector 35.1×
- Promoter holding
- 46.54%-0.83% QoQ
- FII holding
- 0.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shivalik Rasayan Ltd
All →Shivalik Rasayan Board Meeting Date
Shivalik Rasayan intimated a board meeting on 13 November 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window remains closed until 48 hours after results.
Shivalik Rasayan Business Update
Shivalik Rasayan achieved USFDA Complete Assessment for its Avapritinib API Drug Master File. The API is used in Sanofi's GIST treatment Ayvakit.
Shivalik Rasayan Other Announcement
The company filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required under SEBI listing regulations.
Shivalik Rasayan Capital Structure Change
Ginnerup Capital ApS acquired 3,99,990 fully convertible warrants of Shivalik Rasayan Limited. The acquisition via preferential allotment represents a 5.34% stake on a diluted basis.
Shivalik Rasayan Annual General Meeting
Shivalik Rasayan Limited conducted its 48th Annual General Meeting on September 28, 2026. Key resolutions included the adoption of financial statements and declaration of a 10% dividend.
Shivalik Rasayan Other Announcement
Shivalik Rasayan Ltd filed its quarterly shareholding pattern as per SEBI regulations. This is a routine compliance disclosure.